If a phase III clinical trial drug with as much anecdotal and clinical evidence as to its efficacy thus far, together with Mozz’s veritable suite of further possibilities for the drug, cannot get a financial backer at the moment then let’s just say it’s not the science holding us back….time to deliver PR and it does need to be in the very near future…and yes you absolutely will need to give up some control so big boy pants on PR…my thoughts
Ann: Appendix 4D and Half Year Report, page-39
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.005(1.69%) |
Mkt cap ! $112.9M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 31.0¢ | 28.5¢ | $431.5K | 1.469M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 21578 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 9000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| PAR (ASX) Chart |